Cancer Stem Cells in Acute Leukemia
| Status: | Recruiting |
|---|---|
| Conditions: | Other Indications, Blood Cancer |
| Therapuetic Areas: | Oncology, Other |
| Healthy: | No |
| Age Range: | Any - 30 |
| Updated: | 11/10/2018 |
| Start Date: | July 12, 2017 |
| End Date: | July 1, 2022 |
| Contact: | Kimberly Van Iperen |
| Email: | kimberly.vaniperen@sanfordhealth.org |
| Phone: | 605-312-1081 |
Descriptive study of acute leukemia patients. Bone marrow aspirate or peripheral blood
samples will be analyzed by next-generation sequencing for novel gene signatures and
variations in transcriptional and epigenetic regulatory elements such as ARID5B and SALL4
variants.
samples will be analyzed by next-generation sequencing for novel gene signatures and
variations in transcriptional and epigenetic regulatory elements such as ARID5B and SALL4
variants.
Inclusion Criteria:
- Newly diagnosed or relapsed acute leukemia (AML or ALL)
- Plan to undergo diagnostic bone marrow aspirate or peripheral blood if clinically
indicated (i.e. WBC>50,000 and bone marrow contraindicated)
- Age 1 month to 30 years
- Understand and provide informed consent (subject if>18, legal guardian if<18)
Exclusion Criteria:
- Age 0 to 4 weeks
- Treatment related leukemia or leukemia secondary to MDS
- Situations that would limit compliance with study requirements or ability to willingly
give consent
We found this trial at
1
site
Sioux Falls, South Dakota 57104
Principal Investigator: Samuel Milanovich, MD
Phone: 605-312-1081
Click here to add this to my saved trials
